This purpose of this study is to evaluate the role of gemcitabine and docetaxel, a well tolerated chemotherapy regimen in the treatment of advanced non-small cell lung cancer (NSCLC), in combination with a novel agent cetuximab.
Upon determination of eligibility all patients will receive: * Docetaxel + Gemcitabine + Cetuximab
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
69
1000mg/m2 30min IV, Day 1 \& 8
30mg/m2, 30min IV, day 1 \& 8
100mg/m2 IV, Cycle 1 Day 1, 250mg/m2 IV day 8 \& 15, all subsequent cycles 250mg/m2 IV day 1, 8, \& 15
Northeast Alabama Regional Medical Center
Anniston, Alabama, United States
Northeast Arkansas Clinic
Jonesboro, Arkansas, United States
Florida Cancer Specialists
Fort Myers, Florida, United States
Overall Clinical Response Rate
Overall response rate was defined as the proportion of treated patients whose best response was a complete or partial response after completing at least two courses of treatment.
Time frame: 18 months
Progression Free Survival (PFS)
Progression free survival was defined as the interval between the start date of treatment and the date of occurrence of progressive disase or death from any cause.
Time frame: 18 months
Response Duration
The Response Duration was calculated from time of initial measured response to date of first observation of progressive disease.
Time frame: 18 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Gainsville Hematology Oncology Associates
Gainesville, Florida, United States
Northeast Georgia Medical Center
Gainesville, Georgia, United States
Graves-Gilbert Clinic
Bowling Green, Kentucky, United States
Consultants in Blood Disorders and Cancer
Louisville, Kentucky, United States
Mercy Hospital
Portland, Maine, United States
Consultants in Medical Oncology and Hematology
Drexel Hill, Pennsylvania, United States
Tennessee Oncology, PLLC
Nashville, Tennessee, United States